On April 27, 2026 AstraZeneca (NYSE: AZN) reported that the China National Medical Products Administration has officially approved Imfinzi (Imfinzi,Durvalumab in combination with ImjudoTrimelimab is used as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma (HCC). In addition,Durvalumab has also been approved as monotherapy for first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC). In early April, this combination regimen was approved in China, along with platinum-based chemotherapy, for first-line treatment of metastatic non-small cell lung cancer (NSCLC) that is negative for epidermal growth factor receptor (EGFR) sensitive mutations and anaplastic lymphoma kinase (ALK).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This approval is based on the results of the global Phase III clinical trial HIMALAYA and the Chinese cohort. Global cohort data shows that, compared to…Compared with sorafenib monotherapy , the STRIDE regimen significantly reduced the risk of death by 22% in patients (hazard ratio [HR] 0.78; 95% confidence interval [CI], 0.66–0.92; p = 0.0035). (Single dose)Trimerumab combined with fixed intervalThe median overall survival (OS) in the durvalumab (STRIDE) combination therapy group was 16.4 months, whileThe sorafenib group had a duration of 13.8 months.durvalumab monotherapy compared toSorafenib demonstrated a non-inferiority benefit in overall survival (OS) (HR 0.86; 95% CI, 0.73–1.02), with a pre-specified non-inferiority margin of 1.08 (based on the upper limit of 95.67% CI).The median overall survival (OS) in the durvalumab monotherapy group was 16.6 months.

The HIMALAYA study’s Chinese cohort analysis showed a clear long-term benefit trend for the STRIDE regimen, consistent with the global benefit trend. The median overall survival (OS) in the STRIDE combination therapy group was 25.3 months, compared to…In the sorafenib group (median OS of 14.1 months), the survival time was extended by more than 11 months, with a 40% reduction in the risk of death (HR=0.60; 95% CI, 0.42-0.84), and the 3-year OS rate reached 40.6%, approximately [missing data].Twice that of the sorafenib control group. In terms of safety, the STRIDE regimen is comparable to…Durvalumab monotherapy demonstrated good safety and tolerability in both groups. Data showed that the STRIDE regimen group and…The incidence of grade 3 or higher treatment-related adverse events (TRAE) in the durvalumab monotherapy group was 24.1% and 12.4%, respectively, both lower than that in the control group.40.2% in the Sorafenib group.

(Press release, AstraZeneca, APR 27, 2026, View Source;utm_source=official [SID1234665019])

On April 27, 2026 Jecho Laboratories, Inc. ("Jecho"), a clinical-stage biotechnology company focused on developing innovative therapeutics, reported that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for JLM019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JLM019 is a CD80/PD-1 dual-target Fc fusion protein with a unique bidirectional synergistic mechanism. With its precise targeting design, the drug is expected to overcome the limitations of existing immunotherapies, improve immunotherapy response rates, and delay the development of tumor cell resistance. As a result, it has the potential to significantly enhance immunotherapy and provide new treatment options and hope for survival for patients with advanced solid tumors and lymphomas.

JLM019 is currently in a Phase 1 study for advanced malignant tumors in Peking Union Medical College Hospital, as it was approved to commence clinical trials by China’s National Medical Products Administration (NMPA) in September 2025. The Phase 1 study is designed to evaluate the safety, tolerability, and preliminary efficacy of JLM019 injection in patients with advanced malignancies.

This achievement marks the third U.S. FDA IND clearance Jecho has obtained and the 11th overall IND clearance.

(Press release, Jecho Laboratories, APR 27, 2026, View Source [SID1234664969])

On April 27, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The details of the poster presentation sessions and publish-only abstracts are listed below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
Session Type/Title: Poster Session – Breast Cancer—Metastatic
Poster Board: 222
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT

Abstract Title: Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
Session Type/Title: Poster Session – Breast Cancer—Metastatic
Poster Board: 221
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT

Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
Session Type/Title: Poster Session – Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT

Publication-Only Abstract Title: Cell-based second-generation immunotherapy BC1 in metastatic breast cancer.

Publication-Only Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.

Publication-Only Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.

Presentation details will become available upon publication of the abstracts by ASCO (Free ASCO Whitepaper) on May 21, 2026 at 5:00 PM ET.

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, APR 27, 2026, View Source [SID1234664854])

On April 27, 2026 Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, reported the pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at a price of $6.00 per share. The gross proceeds from the offering are expected to be approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering are to be sold by Sagimet. The offering is expected to close on or about April 28, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing included participation from new and existing investors, including Balyasny Asset Management, Blue Owl Healthcare Opportunities, BVF Partners L.P., Caligan Partners, Coastlands Capital, Farallon Capital Management, Great Point Partners, LLC, Woodline Partners LP and a Large Mutual Fund.

Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Canaccord Genuity, H.C. Wainwright & Co. and Jones are acting as co-lead managers for the offering.

Sagimet intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, fund TVB-3567 through Phase 2 topline results, advance a topical formulation FASN inhibitor to IND submission and for general corporate purposes, including additional clinical development, working capital and operating expenses. The Company currently expects that its existing cash and cash equivalents, together with the proceeds from the offering, will fund its acne programs through 2028 and the readout of the Company’s planned denifanstat Phase 3 clinical trial in moderate to severe acne.

A shelf registration statement on Form S-3 (File No. 333-281582) relating to these shares was filed with the Securities and Exchange Commission (the "SEC") and declared effective on August 26, 2024. A prospectus supplement relating to the offering, and the accompanying prospectus, will be filed with the SEC. When available, copies of the prospectus supplement and accompanying prospectus may also be obtained from the offices of Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor will there be any sale of these shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state, province, territory or other jurisdiction.

(Press release, Sagimet Biosciences, APR 27, 2026, View Source [SID1234664836])

On April 27, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The details of the poster presentation sessions and publish-only abstracts are listed below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
Session Type/Title: Poster Session – Breast Cancer—Metastatic
Poster Board: 222
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT

Abstract Title: Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
Session Type/Title: Poster Session – Breast Cancer—Metastatic
Poster Board: 221
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT

Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
Session Type/Title: Poster Session – Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT

Publication-Only Abstract Title: Cell-based second-generation immunotherapy BC1 in metastatic breast cancer.

Publication-Only Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.

Publication-Only Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.

Presentation details will become available upon publication of the abstracts by ASCO (Free ASCO Whitepaper) on May 21, 2026 at 5:00 PM ET.

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, APR 27, 2026, View Source [SID1234664835])